Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab-Based Therapy with Targeted Agents in R/R LBCL
NCT05890352Phase 2Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Sep 2023
- Primary completion
- Dec 2029
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tazemetostat and zanubrutinib in diffuse large B-cell lymphoma (DLBCL) (5 arms), sponsored by SWOG Cancer Research Network. Primary endpoints: Progression-Free Survival at 3 years and Functional Assessment of Cancer Therapy-Lymphoma Trial Outcome Index at 3 months. Started Sep 2023; status: recruiting.
02
Drugs
tazemetostatzanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05890352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05890352.